Dr Metersky provides an overview of current treatment strategies for managing patients diagnosed with bronchiectasis. The main bronchiectasis management goals are improving quality of life, decreasing ...
A pulmonary specialist shares his approach to treating patients with bronchiectasis, highlighting gaps in knowledge that impact management practices. What are the current gaps in knowledge regarding ...
Please provide your email address to receive an email when new articles are posted on . From weeks 17 to 62 of treatment, azithromycin was highly effective in children with bronchiectasis. Birth ...
— BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network — — Insmed (INSM) to Host Investor ...
Bronchiectasis is one of the most common highly heterogeneous chronic inflammatory airway diseases in China. It has a long course, heavy symptom burden, and is prone to recurrent acute exacerbations, ...
The ASPEN randomized trial showed that novel brensocatib cut the annualized rate of pulmonary exacerbations by around 20% compared with placebo. Brensocatib is a DPP-1 inhibitor that works by reducing ...
— If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophilic ...
CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic fibrosis bronchiectasis at its higher dose, a CT substudy of the ASPEN trial ...
— BRINSUPRI Was Reviewed Under EMA's Accelerated Assessment Pathway as It Is Considered of Major Interest for Public Health — BRIDGEWATER, N.J., Nov. 18, 2025 /PRNewswire/ -- Insmed Incorporated (INSM ...
DelveInsight’s, “Non‐cystic fibrosis bronchiectasis Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Non‐cystic fibrosis bronchiectasis ...
Insmed's freshly approved lung condition drug soared past sales expectations for 2025, netting $144.6 million in its first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results